Guangdong Biolight Meditech Co., Ltd. (SHE:300246)
China · Delayed Price · Currency is CNY 8.38
-0.15 (-1.76%)
Sep 23, 2025, 2:45 PM CST
SHE:300246 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -67.61 | -71.44 | -65.19 | 22.13 | 63.79 | 346.15 | Upgrade |
Depreciation & Amortization | 69.32 | 66.89 | 58.12 | 51.24 | 40.5 | 17.69 | Upgrade |
Other Amortization | 12.39 | 11.62 | 9.44 | 8.17 | 5.2 | 6.08 | Upgrade |
Loss (Gain) From Sale of Assets | 0.77 | -0.03 | 0.31 | -0.51 | -0.92 | 0.06 | Upgrade |
Asset Writedown & Restructuring Costs | 20.82 | 20.82 | 114.55 | 0.01 | 9.54 | 1.57 | Upgrade |
Loss (Gain) From Sale of Investments | -7.08 | -9.99 | -10.31 | -9.98 | 0.45 | -0.99 | Upgrade |
Provision & Write-off of Bad Debts | 4.6 | 4.5 | 6.32 | 6.5 | 3.52 | 2.64 | Upgrade |
Other Operating Activities | 39.8 | 37.27 | 29.71 | 19.26 | 18.38 | 34.24 | Upgrade |
Change in Accounts Receivable | 282.61 | 27.39 | -42.69 | -58.27 | -50.72 | -11.86 | Upgrade |
Change in Inventory | -47.59 | -21.97 | -26.78 | -6.15 | -45.95 | -52.06 | Upgrade |
Change in Accounts Payable | -291.3 | -62.49 | 52.24 | 109.61 | 27.85 | 109.59 | Upgrade |
Change in Other Net Operating Assets | - | - | -4.89 | 7.3 | 13.25 | - | Upgrade |
Operating Cash Flow | 4.99 | -8.64 | 129.05 | 140.72 | 80.61 | 455.78 | Upgrade |
Operating Cash Flow Growth | -94.74% | - | -8.30% | 74.56% | -82.31% | 459.75% | Upgrade |
Capital Expenditures | -156.19 | -103.81 | -220.33 | -211.8 | -163.41 | -68.45 | Upgrade |
Sale of Property, Plant & Equipment | 13.08 | 0.49 | 0.03 | 4.49 | 3.62 | 0 | Upgrade |
Cash Acquisitions | - | - | -1.03 | - | -0.09 | -110.7 | Upgrade |
Divestitures | 0.18 | 0.18 | - | - | - | - | Upgrade |
Investment in Securities | 244.37 | 59.37 | 30 | -289.4 | -21.3 | -25 | Upgrade |
Other Investing Activities | 26.4 | 8.35 | 1.09 | 0.3 | -11.99 | -0.74 | Upgrade |
Investing Cash Flow | 127.83 | -35.43 | -190.24 | -496.41 | -193.17 | -204.88 | Upgrade |
Long-Term Debt Issued | - | 427.53 | 371.04 | 204.59 | 215.89 | 287.08 | Upgrade |
Total Debt Issued | 298.62 | 427.53 | 371.04 | 204.59 | 215.89 | 287.08 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | -29.57 | - | Upgrade |
Long-Term Debt Repaid | - | -374.55 | -175.1 | -168.71 | -128.9 | -196.68 | Upgrade |
Total Debt Repaid | -411.37 | -374.55 | -175.1 | -168.71 | -158.47 | -196.68 | Upgrade |
Net Debt Issued (Repaid) | -112.74 | 52.98 | 195.94 | 35.89 | 57.42 | 90.4 | Upgrade |
Issuance of Common Stock | - | - | 7.87 | 543.87 | - | - | Upgrade |
Repurchase of Common Stock | -0.36 | -20.01 | - | - | - | - | Upgrade |
Common Dividends Paid | -12.54 | -17.62 | -46.35 | -40.83 | -58.35 | -33.17 | Upgrade |
Other Financing Activities | -10.25 | 6.28 | -39.91 | -52.23 | -43.56 | -19.85 | Upgrade |
Financing Cash Flow | -135.9 | 21.63 | 117.55 | 486.7 | -44.5 | 37.38 | Upgrade |
Foreign Exchange Rate Adjustments | 2.4 | 3.47 | 1.18 | 4.78 | -1.21 | -10.17 | Upgrade |
Net Cash Flow | -0.68 | -18.98 | 57.53 | 135.8 | -158.27 | 278.1 | Upgrade |
Free Cash Flow | -151.2 | -112.45 | -91.29 | -71.08 | -82.8 | 387.33 | Upgrade |
Free Cash Flow Growth | - | - | - | - | - | 1025.08% | Upgrade |
Free Cash Flow Margin | -14.44% | -10.60% | -7.65% | -6.00% | -7.59% | 27.75% | Upgrade |
Free Cash Flow Per Share | -0.58 | -0.43 | -0.35 | -0.27 | -0.38 | 1.76 | Upgrade |
Cash Income Tax Paid | 10.27 | 8.51 | 20.72 | 7.48 | 30.71 | 65.18 | Upgrade |
Levered Free Cash Flow | -232.99 | -189.62 | -89.93 | -130.32 | -124.77 | 248.64 | Upgrade |
Unlevered Free Cash Flow | -216.12 | -172.51 | -80.63 | -123.13 | -117.29 | 256.46 | Upgrade |
Change in Working Capital | -68.02 | -68.27 | -13.91 | 43.89 | -59.83 | 48.36 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.